Can ctDNA detect colorectal cancer recurrence earlier?

Can ctDNA detect colorectal cancer recurrence earlier? Yes. Circulating tumor DNA (ctDNA) blood tests can sometimes identify molecular signs of colorectal cancer recurrence months before tumors become visible on conventional imaging. But detecting recurrence earlier does not automatically mean that treatment decisions based on the result improve survival.

Researchers are investigating how ctDNA can detect colorectal cancer recurrence before conventional imaging identifies a visible tumor. Studies increasingly support ctDNA as a marker of molecular residual disease after treatment, although its ability to guide decisions and improve survival requires further evidence.

THE SHORT ANSWER

After colorectal cancer surgery, chemotherapy or local treatment of metastases, microscopic cancer cells may remain even when scans show no detectable disease.

Some of these cells release fragments of DNA into the bloodstream. Sensitive ctDNA assays may detect those fragments before a recurrent tumor becomes large enough to appear on CT or MRI.

WHAT IS ctDNA?

Circulating tumor DNA is DNA released into the bloodstream by cancer cells.

It represents a small fraction of cell-free DNA, which also includes DNA released by healthy cells.

Specialized assays search for cancer-associated mutations, methylation patterns or other molecular signals.

Unlike a tissue biopsy, ctDNA testing usually requires only a blood sample.

However, not all liquid biopsy tests serve the same purpose. A test designed to identify treatment-related mutations in advanced cancer is not necessarily validated for detecting molecular residual disease after surgery.

HOW ctDNA CAN DETECT COLORECTAL CANCER RECURRENCE

To understand how ctDNA can detect colorectal cancer recurrence, it is important to understand molecular residual disease, or MRD.

MRD refers to evidence of cancer-related molecular material remaining after treatment, even when conventional imaging shows no detectable tumor.

For example, a patient may have:

• Complete surgical removal of the primary tumor
• No suspicious findings on postoperative imaging
• A normal CEA tumor marker
• A positive tumor-specific ctDNA result

This pattern raises concern for microscopic residual cancer, but it does not identify its location or prove that a visible recurrence is already present.

CAN ctDNA DETECT COLORECTAL CANCER RECURRENCE EARLIER? WHAT RESEARCH SHOWS

1. GALAXY: ctDNA predicts recurrence risk

Research from the CIRCULATE-Japan GALAXY program has demonstrated strong associations between postoperative ctDNA positivity and colorectal cancer recurrence.

In a study of patients with resected Stage II or III colorectal cancer, a tumor-naïve ctDNA assay detected molecular recurrence a median of approximately 4.77 months before clinical recurrence in the relevant longitudinal analysis.

The study also reported stronger prognostic associations for ctDNA than for CEA in its analyzed population.

2. A 2026 assay-validation study

A separate GALAXY-based validation study involving 195 patients evaluated a tissue-free methylation-based ctDNA assay.

During longitudinal surveillance, the reported sensitivity for recurrence detection was 84.4%, with a median lead time of 4.6 months.

These findings support the potential value of repeated testing while showing that some recurrences remain undetected.

3. FIND: randomized evidence for earlier detection

The randomized Phase III FIND trial evaluated ctDNA-guided postoperative surveillance compared with conventional CT-based monitoring in patients with initially nonmetastatic colorectal cancer.

Among 584 eligible participants, recurrence was detected earlier in the ctDNA-guided group, with a reported median difference of 3.9 months.

A greater proportion of patients with recurrence underwent treatment intended to eliminate recurrent disease.

These studies differ in their populations, assays and follow-up schedules. Their results should not be assumed to apply equally to every patient.

DOES EARLIER DETECTION IMPROVE SURVIVAL?

This remains one of the most important questions.

A test can detect recurrence earlier without necessarily improving the final outcome.

Researchers distinguish between three concepts:

• Analytical validity: Can the assay accurately detect the molecular signal?
• Clinical validity: Does that signal predict recurrence?
• Clinical utility: Does acting on the result improve outcomes that matter to patients?

ctDNA has substantial evidence supporting clinical validity in colorectal cancer.

Evidence of clinical utility is developing and varies by disease stage and treatment setting.

WHAT DOES A POSITIVE ctDNA RESULT MEAN?

After apparently complete treatment, a positive MRD ctDNA test may indicate a substantially higher risk of recurrence.

Interpretation depends on:

• The assay’s clinical validation and specificity
• Whether the result is newly positive or persistently positive
• When the sample was collected
• Recent surgery or chemotherapy
• Imaging results and clinical history

Doctors may consider additional evaluation, repeat testing, imaging review or clinical-trial participation.

A positive result alone does not establish that additional chemotherapy or surgery will benefit every patient.

WHAT DOES A NEGATIVE ctDNA RESULT MEAN?

A negative result means the assay did not detect its targeted cancer-related signal in that particular blood sample.

It does not prove that all cancer cells have been eliminated.

Although ctDNA can detect colorectal cancer recurrence earlier in some patients, a negative result cannot exclude microscopic disease because not every tumor releases enough detectable DNA into the bloodstream.

Possible reasons for a false-negative result include:

• Very low concentrations of tumor-derived DNA
• Limited shedding of DNA into blood
• Differences in tumor location and biology
• Assay sensitivity limitations
• Timing relative to treatment

IS ctDNA BETTER THAN CEA?

CEA is a tumor-associated blood marker used during colorectal cancer follow-up.

Some patients with recurrence have normal CEA values, while certain noncancerous conditions can increase CEA.

ctDNA can provide a more tumor-specific molecular signal and has shown stronger associations with recurrence in several studies.

However, the tests measure different biological processes and are not universally interchangeable.

ARE ALL ctDNA TESTS EQUALLY ACCURATE?

No. Assays differ in the molecular signals they measure and how they are developed.

Tumor-informed assays

These assays use a patient’s tumor tissue to identify molecular alterations that can subsequently be tracked in blood.

Tumor-naïve assays

These assays do not require a personalized tumor mutation profile and may use predefined mutations, methylation patterns or other molecular characteristics.

Diagnostic accuracy can differ according to the assay, clinical setting and frequency of blood sampling.

HOW OFTEN SHOULD ctDNA BE TESTED?

There is no single universally appropriate schedule for all colorectal cancer survivors.

Research protocols have evaluated blood collection several weeks after surgery and at regular intervals during surveillance.

The appropriate schedule depends on the test, treatment setting, recurrence risk and whether the result could change management.

Very early postoperative testing can be harder to interpret because tissue injury temporarily increases background cell-free DNA.

WHAT ABOUT STAGE IV COLORECTAL CANCER?

ctDNA is also being investigated after complete local treatment of metastatic colorectal cancer, including liver metastases.

This may be relevant when surgery or ablation has treated all visible lesions and subsequent imaging shows no evidence of disease.

A positive ctDNA result after metastasis-directed treatment may indicate a higher risk of recurrence.

However, findings from initially nonmetastatic Stage II–III disease cannot automatically be generalized to patients treated for Stage IV cancer.

The optimal role of ctDNA after metastatic resection or ablation remains under investigation.

CAN ctDNA IDENTIFY WHERE RECURRENCE IS LOCATED?

Usually not.

A positive MRD ctDNA result can indicate the presence of a cancer-related molecular signal without showing the anatomical location of the disease.

Imaging and other investigations are needed to identify a lesion that may be treated.

SHOULD TREATMENT START JUST BECAUSE ctDNA IS POSITIVE?

Not automatically.

Some randomized studies have demonstrated that ctDNA-guided approaches can help refine postoperative treatment decisions in selected settings.

For example, the DYNAMIC trial in Stage II colon cancer demonstrated that ctDNA-guided management reduced chemotherapy use without compromising recurrence-free survival in the studied population.

However, treatment escalation based solely on ctDNA positivity has not consistently been shown to improve outcomes across all settings.

Decisions should consider stage, prior treatment, molecular findings, imaging, patient preferences and clinical-trial availability.

QUESTIONS TO ASK YOUR ONCOLOGIST

THE BOTTOM LINE

RELATED CANCERSNOOP ARTICLES

SCIENTIFIC SOURCES

LAST REVIEWED
October 16, 2026